Sorafenib: A Review in Hepatocellular Carcinoma

被引：271

作者：

Keating, Gillian M. ^{[1
]}

机构：

[1] Springer, Private Bag 65901,Mairangi Bay 0754, Auckland, New Zealand

来源：

TARGETED ONCOLOGY | 2017年 / 12卷 / 02期

关键词：

PHASE-III; CLINICAL-PRACTICE; LIVER-FUNCTION; TRANSARTERIAL CHEMOEMBOLIZATION; THERAPEUTIC DECISIONS; RAF/MEK/ERK PATHWAY; JAPANESE PATIENTS; TREATED PATIENTS; CONTROLLED-TRIAL; PATIENT SUBSET;

D O I：

10.1007/s11523-017-0484-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sorafenib (Nexavar(A (R))) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall survival (OS) and time to radiological progression (TTP) with sorafenib 400 mg twice daily than with placebo, with no significant between-group difference in the median time to symptomatic progression (TTSP). Subsequent results from real-world studies such as GIDEON also support the use of sorafenib in HCC, including in carefully selected CP class B patients, although the median OS achieved in these patients appears relatively short. Sorafenib has a well characterized tolerability and safety profile, with strategies available to prevent and manage adverse effects such as hand-foot skin reactions. In conclusion, sorafenib remains an important option for the treatment of HCC.

引用

页码：243 / 253

页数：11

共 69 条

[31] Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives [J].

Hsu, Chih-Hung ;

Shen, Ying-Chun ;

Shao, Yu-Yun ;

Hsu, Chiun ;

Cheng, Ann-Lii .

JOURNAL OF HEPATOCELLULAR CARCINOMA, 2014, 1 :85-99

[32] Field-Practice Study of Sorafenib Therapy for Hepatocellular Carcinoma: A Prospective Multicenter Study in Italy [J].

Iavarone, Massimo ;

Cabibbo, Giuseppe ;

Piscaglia, Fabio ;

Zavaglia, Claudio ;

Grieco, Antonio ;

Villa, Erica ;

Camma, Calogero ;

Colombo, Massimo ;

Sangiovanni, Angelo ;

Vavassori, Sara ;

Romeo, Raffaella ;

Di Marco, Vito ;

Craxi, Antonio ;

Borghi, Alberto ;

Granito, Alessandro ;

Bolondi, Luigi ;

Airoldi, Aldo ;

Pinzello, Giovambattista ;

Biolato, Marco ;

Racco, Simona ;

Pompili, Maurizio ;

Lei, Barbara ;

De Maria, Nicola .

HEPATOLOGY, 2011, 54 (06) :2055-2063

[33]

Ji You-xin, 2014, Chinese Medical Sciences Journal, V29, P7

[34] Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade [J].

Johnson, Philip J. ;

Berhane, Sarah ;

Kagebayashi, Chiaki ;

Satomura, Shinji ;

Teng, Mabel ;

Reeves, Helen L. ;

O'Beirne, James ;

Fox, Richard ;

Skowronska, Anna ;

Palmer, Daniel ;

Yeo, Winnie ;

Mo, Frankie ;

Lai, Paul ;

Inarrairaegui, Mercedes ;

Chan, Stephen L. ;

Sangro, Bruno ;

Miksad, Rebecca ;

Tada, Toshifumi ;

Kumada, Takashi ;

Toyoda, Hidenori .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) :550-U45

[35] Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study [J].

Johnson, Philip J. ;

Qin, Shukui ;

Park, Joong-Won ;

Poon, Ronnie T. P. ;

Raoul, Jean-Luc ;

Philip, Philip A. ;

Hsu, Chih-Hung ;

Hu, Tsung-Hui ;

Heo, Jeong ;

Xu, Jianming ;

Lu, Ligong ;

Chao, Yee ;

Boucher, Eveline ;

Han, Kwang-Hyub ;

Paik, Seung-Woon ;

Robles-Avina, Jorge ;

Kudo, Masatoshi ;

Yan, Lunan ;

Sobhonslidsuk, Abhasnee ;

Komov, Dmitry ;

Decaens, Thomas ;

Tak, Won-Young ;

Jeng, Long-Bin ;

Liu, David ;

Ezzeddine, Rana ;

Walters, Ian ;

Cheng, Ann-Lii .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) :3517-+

[36] Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study [J].

Kaneko, Shuichi ;

Ikeda, Kenji ;

Matsuzaki, Yasushi ;

Furuse, Junji ;

Minami, Hironobu ;

Okayama, Yutaka ;

Sunaya, Toshiyuki ;

Ito, Yuichiro ;

Inuyama, Lyo ;

Okita, Kiwamu .

JOURNAL OF GASTROENTEROLOGY, 2016, 51 (10) :1011-1021

[37] Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data [J].

Kim, Do Young ;

Kim, Hye Jin ;

Han, Kwang-Hyub ;

Han, Sang Young ;

Heo, Jeong ;

Woo, Hyun Young ;

Um, Soon Ho ;

Kim, Yeul Hong ;

Kweon, Young Oh ;

Um, Ho Yeong ;

Yoon, Jung Hwan ;

Lee, Wan Sik ;

Lee, Byung Seok ;

Lee, Han Chu ;

Ryoo, Baek-Yeol ;

Yoon, Seung Kew .

CANCER RESEARCH AND TREATMENT, 2016, 48 (04) :1243-1252

[38] Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma [J].

Kim, Jeong Eun ;

Ryoo, Baek-Yeol ;

Ryu, Min-Hee ;

Chang, Heung-Moon ;

Suh, Dong Jin ;

Lee, Han Chu ;

Lim, Young-Suk ;

Kim, Kang Mo ;

Kang, Yoon-Koo .

ONCOLOGY, 2012, 82 (02) :119-125

[39] Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON [J].

Kudo, Masatoshi ;

Ikeda, Masafumi ;

Takayama, Tadatoshi ;

Numata, Kazushi ;

Izumi, Namiki ;

Furuse, Junji ;

Okusaka, Takuji ;

Kadoya, Masumi ;

Yamashita, Satoshi ;

Ito, Yuichiro ;

Kokudo, Norihiro .

JOURNAL OF GASTROENTEROLOGY, 2016, 51 (12) :1150-1160

[40] Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study [J].

Kudo, Masatoshi ;

Lencioni, Riccardo ;

Marrero, Jorge A. ;

Venook, Alan P. ;

Bronowicki, Jean-Pierre ;

Chen, Xiao-Ping ;

Dagher, Lucy ;

Furuse, Junji ;

Geschwind, Jean-Francois H. ;

Ladron de Guevara, Laura ;

Papandreou, Christos ;

Sanyal, Arun J. ;

Takayama, Tadatoshi ;

Yoon, Seung Kew ;

Nakajima, Keiko ;

Lehr, Robert ;

Heldner, Stephanie ;

Ye, Sheng-Long .

LIVER INTERNATIONAL, 2016, 36 (08) :1196-1205

← 1 2 3 4 5 6 7 →